Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF341 antisense RNA 1 (ZNF341-AS1) is a long non-coding RNA that is transcribed in the antisense direction to the ZNF341 gene[5]. As with most antisense RNAs, it is thought to regulate the expression of its sense counterpart (here, ZNF341), potentially affecting gene expression via chromatin modification, transcriptional interference, or RNA-RNA interactions, although a specific functional role for ZNF341-AS1 has not been directly described in the available literature[3]. There is no evidence that ZNF341-AS1 is currently considered a therapeutic target, used as a biomarker, or has established links to human disease. Antisense RNAs in general can regulate gene expression by influencing transcription, translation, RNA stability, or chromatin structure related to their corresponding sense gene[3]. Most disease associations and therapeutic interest center on the sense gene, ZNF341, rather than ZNF341-AS1[1][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF341 antisense RNA 1 (ZNF341-AS1).